CDKN2A and melanoma: The CDK4 pathway comprising of signaling components like p16INK4a-cyclin D-CDK4/6-retinoblastoma is known to be altered in 90% of human melanomas [19], while 15–20% of melanoma cases show mutations in the NRAS gene [20].